AARS2 ameliorates myocardial ischemia via fine-tuning PKM2-mediated metabolism
eLife · 2025
DOI: 10.7554/elife.99670 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Zongwang Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, College of Future Technology, Academy for Advanced Int…. Hauptthemen laut MEDLINE: Myocardial Ischemia, Pyruvate Kinase, Thyroid Hormones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
AARS2, an alanyl-tRNA synthase, is essential for protein translation, but its function in mouse hearts is not fully addressed. Here, we found that cardiomyocyte-specific deletion of mouse AARS2 exhibited evident cardiomyopathy with impaired cardiac function, notable cardiac fibrosis, and cardiomyocyte apoptosis. Cardiomyocyte-specific AARS2 overexpression in mice improved cardiac function and reduced cardiac fibrosis after myocardial infarction (MI), without affecting cardiomyocyte proliferation and coronary angiogenesis. Mechanistically, AARS2 overexpression suppressed cardiomyocyte apoptosis and mitochondrial reactive oxide species production, and changed cellular metabolism from oxidative phosphorylation toward glycolysis in cardiomyocytes, thus leading to cardiomyocyte survival from ischemia and hypoxia stress. Ribo-Seq revealed that Aars2 overexpression increased pyruvate kinase M2 (PKM2) protein translation and the ratio of PKM2 dimers to tetramers that promote glycolysis. Additionally, PKM2 activator TEPP-46 reversed cardiomyocyte apoptosis and cardiac fibrosis caused by AARS2 deficiency. Thus, this study demonstrates that AARS2 plays an essential role in protecting cardiomyocytes from ischemic pressure via fine-tuning PKM2-mediated energy metabolism, and presents a novel cardiac protective AARS2-PKM2 signaling during the pathogenesis of MI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, College of Future Technology, Academy for Advanced Interdisciplinary Studies, and State Key Laboratory of Natural and Biomim…
- School of Basic Medical Sciences and The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Obstetrics and Gynecology Hospital of Fudan University, State Key Lab of Genetic Engineering, School of Life Sciences and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
ORCID-Profile: Zongwang Zhang, Yang Chen, Jing-Wei Xiong
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Z., Zheng, L., Chen, Y., Chen, Y., Hou, J., Xiao, C., Zhu, X., Zhao, S. M., & Xiong, J. W. (2025). AARS2 ameliorates myocardial ischemia via fine-tuning PKM2-mediated metabolism. eLife. https://doi.org/10.7554/elife.99670
Vancouver
Zhang Z, Zheng L, Chen Y, Chen Y, Hou J, Xiao C, et al. AARS2 ameliorates myocardial ischemia via fine-tuning PKM2-mediated metabolism. eLife. 2025. doi:10.7554/elife.99670
BibTeX
@article{Zhang2025,
author = {Zhang, Zongwang and Zheng, Lixia and Chen, Yang and Chen, Yuanyuan and Hou, Junjie and Xiao, Chenglu and Zhu, Xiaojun and Zhao, Shi-Min and Xiong, Jing-Wei},
title = {AARS2 ameliorates myocardial ischemia via fine-tuning PKM2-mediated metabolism},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.99670}
}
EUVIMED